Recap/Summary Recent Stuff 1. 6qm PR DMSC positiv
Post# of 148288
(Total Views: 569)
Posted On: 10/21/2020 11:05:42 AM
Recap/Summary Recent Stuff
1. 6qm PR DMSC positive review. Another interim review at 290, add endpoint of 42 days. Statisitcal significance likely to occur at that point (imho).
2. Peer reviewed PAPER released. The great Dr. Yang from UCLA lead author. Oxford Press! No more criticism.
3. NP makes another new, strong appearance on Fox Business 4:45PM, reason for delay in CC.
4. We learn the 5 UK hospitals should be online in a matter of days. This will make a total of 20 hospitals recruiting. Now that Remdesivir is proving to be a fail in stopping mortality, enrollment may accelerate. Teams will be put in place to help push enrollment. Target of 60 by December.
5. We learn CYDY has hired a ringer to help with the HIV BLA application. Meeting with MHRA in UK in 6 days for pre BLA HIV meeting.
6. We learn CYDY has hired a Chief Scientific Officer with deep experienced with BigPharma and UPenn. Very experienced person. Shareholders should be happy
7. We learn that a new PR firm has been hired to assist with well PR.
8. Protocol for Phase 3 moderate trial should be done end of next week.
9. New format for Webcast was a smash hit
10. Dr. Kelly throws some shade on CCR5 by talking about inflammation markers and how inflammation is at the root of so many ailments. We need more science discussion.
11. Media coverage initiated and hopefully will gather momentum, Nader on Fox News twice in the past 10 day, that is huge
1. 6qm PR DMSC positive review. Another interim review at 290, add endpoint of 42 days. Statisitcal significance likely to occur at that point (imho).
2. Peer reviewed PAPER released. The great Dr. Yang from UCLA lead author. Oxford Press! No more criticism.
3. NP makes another new, strong appearance on Fox Business 4:45PM, reason for delay in CC.
4. We learn the 5 UK hospitals should be online in a matter of days. This will make a total of 20 hospitals recruiting. Now that Remdesivir is proving to be a fail in stopping mortality, enrollment may accelerate. Teams will be put in place to help push enrollment. Target of 60 by December.
5. We learn CYDY has hired a ringer to help with the HIV BLA application. Meeting with MHRA in UK in 6 days for pre BLA HIV meeting.
6. We learn CYDY has hired a Chief Scientific Officer with deep experienced with BigPharma and UPenn. Very experienced person. Shareholders should be happy
7. We learn that a new PR firm has been hired to assist with well PR.
8. Protocol for Phase 3 moderate trial should be done end of next week.
9. New format for Webcast was a smash hit
10. Dr. Kelly throws some shade on CCR5 by talking about inflammation markers and how inflammation is at the root of so many ailments. We need more science discussion.
11. Media coverage initiated and hopefully will gather momentum, Nader on Fox News twice in the past 10 day, that is huge
(14)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼